您好,欢迎来到佐思信息
全国服务热线:
400-009-0050
佐思信息专注支持企业决策
您当前的位置:首页>>研究报告>>癌症

2016-2026年胃癌药物研发及市场趋势研究报告
Gastric Cancer Drugs - R&D, Trends and Market Forecasts 2016-2026

2016-2026年胃癌药物研发及市场趋势研究报告
【报告编号】:No.25878
【发布时间】:2016-06
【关 键 字】:Gastric Cancer    胃癌        
【报告页数】:147页
【报告价格】:电子版:2639美元
【交付方式】:Email发送或EMS快递
【订购热线】:


400-009-0050(全国24小时服务)
北京:010-82863481
上海:021-64871266 021-64872612

报告目录下载订购协议下载在线咨询

    专业、专注于为企业提供真正有价值的全球市场调查信息,是我们的使命。我们是中国第一家汇集全球众多行业研究机构研究成果的平台,致力于为企业决策提供最有效的市场资讯,特别是为中国企业了解和进入国际市场迈出第一步,提供全面的信息参考,我们跨越语言及时间的障碍,在信息爆炸的当下,努力为客户提供最有价值的全球产业资讯。我们公司也拥有独立的研究机构,聚焦于中国市场的研究,为国内外企业在中国市场大展宏图提供市场研究支持。

• 我们在全球的合作伙伴>>• 我们的研究中心>>

  • 英文摘要
  • 中文摘要
  • 索取简版报告
  • 癌症行业的相关报告
DESCRIPTION
 
Gastric Cancer Therapies - What R&D Progress and Future Revenues Are Possible?
 
Are you interested in the gastric cancer drug market's future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies. You also explore trends, results and R&D, discovering opportunities and prospects.
 
Visiongain's study gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those anticancer drugs for the human digestive tract can achieve.
 
Please read on now to explore the stomach cancer drugs industry and see what future revenue its fast expanding market could generate.
 
 
Original analysis to benefit your research, plans, decisions and proposals
 
The future holds great potential for pharmaceutical companies treating gastric cancer. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2016, revenues and other progress that are possible.
 
Besides revenue forecasting to 2026, our new work shows you recent results, sales growth rates and market shares. In particular, there, you assess research and development. And our 146 page report gives you 71 tables, 38 charts and a research interview.
 
Our new study's purpose is to help your research, analyses and decisions on gastric cancer therapies, benefiting your authority and reputation for commercial insight. That way you can stay ahead in knowledge to help you stand out and succeed.
 
The following sections show how our new investigation benefits your work.
 
Forecasts covering the overall world market and segments for treating gastric cancer
 
Discover in our new analysis revenue predictions to 2026 for gastric cancer submarkets at world level, as well as a prediction for overall world sales. See what is possible for these four segments:
Monoclonal antibodies (mAbs)
Angiogenesis inhibitors
Chemotherapy
Pipeline candidates and other agents.
 
Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and outlooks. Discover, from 2016, what is possible for that market's progress and success.
 
With a rising incidence of gastric cancer, the demand for better and more-widely available treatments will benefit that industry and market. Explore prospects for patients, healthcare providers and pharma companies.
 
Our new investigation also shows you revenue predications by product, examining how those agents can succeed.
 
Forecasts for leading drugs - what sales are possible?
 
How will individual gastric cancer medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of these seven products:
Herceptin (trastuzumab) - Roche
Cyramza (ramucirumab) - Eli Lilly
Taxotere (docetaxel) - Sanofi
Xeloda (capecitabine) - Roche
Abraxane (paclitaxel protein-bound particle) - Celgene/Taiho Pharmaceutical/Otsuka Pharmaceutical
TS-1/S-1 - Taiho Pharmaceutical/Otsuka Pharmaceutical
Apatinib (YN968D1) - Jiangsu Hengrui Medicine/LSK BioPartners/Bukwang Pharmaceutical Co.
 
In our study you see how high revenues can go, including those for targeted therapies, finding products and years with highest predicted sales. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.
 
Discover what the future holds for treating gastric cancer. Our work also shows you geographical sales predictions.
 
National markets - what outlooks for those anticancer drug revenues?
 
Advances in the biopharma industry expand the range and use of medicines to treat gastric cancer in developed and developing countries. Our work shows you individual revenue forecasts to 2026 for 11 leading national markets:
 
The United States
Japan
Germany, the United Kingdom, France, Italy and Spain (EU5 countries)
Brazil, Russia, India and China (BRIC group).
With our study you assess regions with highest revenues and potential sales growth. Explore outlooks for treating gastric cancers, including discussions of patients' and healthcare providers' needs.
 
You also examine developments leading to novel and improved gastric cancer drugs.
 
R&D for those anticancer medicines - trends, innovations and progress
 
In our study you investigate research and development on gastric cancer. You examine advances in that oncology, assessing clinical trials and seeing what they show.
 
Our survey discusses 13 medicines in development for gastric cancer, including these agents:
Perjeta (pertuzumab) - Roche
Opdivo (nivolumab/ONO-4538) - Roche
Keytruda (pembrolizumab/MK3475) - Merck/MSD
TAS-118 - Taiho Pharmaceutical/Otsuka Pharmaceutical
TAS-102 - Taiho Pharmaceutical/Otsuka Pharmaceutical
NeuVax (nelipepimut-S) - Galena Biopharma/Dr. Reddy's Laboratories
Ipatasertib (GDC-0068/RG7440) - Genentech/Roche/Array Biopharma
Durvalumab (MEDI4736) - AstraZeneca/MedImmune
Avelumab (MSB0010718C) - Merck KGaA/Pfizer
Claudiximab (IMAB362) - Ganymed Pharmaceutical
Napabucasin (BBI608) - Boston Biomedical
AZD4547 - AstraZeneca
Dovitinib (TKI258) - Novartis.
 
Our work shows you what is possible. R&D gains momentum from rising disease prevalence and other forces making treatments for that cancer more widely used and in greater demand.
 
There explore therapeutic and commercial prospects for treating advanced gastric cancer and gastro oesophageal junction (GOJ) cancer, including adenocarcinoma, and related disease. See, from 2016, what is possible.
 
Events and changes affecting pharmaceutical companies treating gastric cancer
 
Our study explains forces shaping the industry and market, letting you explore what is happening from 2016:
Extension of drugs' use - gaining approval for a wider indication range, including use of predictive biomarkers
Existing products and their futures - leading pharma companies' strategies
Competition to gain drug approvals, especially from the FDA and EMA, including medicines with new targets
Progress in clinical trials - finding the most promising medicines, including drugs with better targeting of tumours and cancerous cells
Patent challenges - protecting intellectual property in a competitive market - the rise of generics and biosimilars
Combination therapies and other developments for biological drugs
Cost challenges - pricing and reimbursement, including proving value and clinical superiority.
You also gain analysis of strengths, weaknesses, opportunities and threats, assessing what drives and restrains that rising anticancer drugs segment.
 
Our work shows you what is possible for leading pharma companies and other specialists in biological drugs for treating gastric cancer.
 
Overall 2020 market value - what revenues are possible?Our work predicts that overall sales of those drugs will reach $3bn in 2020. That market will achieve fast revenue expansion from 2016 to 2026, multiplying in size. With our analysis you discover how high sales can go, seeing what is possible for those pharma companies.
 
In particular you examine leading players in that drug development, production and marketing, including Roche, Sanofi, Eli Lilly, Pfizer and Novartis. See what their futures hold.
 
7 ways Gastric Cancer Drugs - R&D, Trends and Market Forecasts 2016-2026 helps you
 
Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge to benefit your plans, decisions and proposals:
Revenues for gastric cancer drugs to 2026 - assess that overall world market's potential, seeing scope for investments, production and marketing
Submarket revenues to 2026 covering 4 segments - explore treatment categories, seeing their sales outlooks from 2016
Leading products' sales to 2026 - discover predicted revenues of 7 top drugs, assessing how well those medicines can compete and succeed
National market predictions to 2026 for 11 countries in the Americas, Europe and Asia - explore the best regions for demand, sales and growth
Research and development - see progress, trends and prospects in R&D on gastric cancer, finding technological, clinical and commercial possibilities
Companies, news and opinion - examine participants in that rising market, gaining insight to help you stay ahead and benefit your authority
Analysis of what stimulates and restrains that market - assess that industry's challenges and strengths, helping you compete and gain advantages.
 
That study, by our in-house analysts in the UK, gives knowledge to benefit your research and decisions. It shows data you find nowhere else. Gain information leading companies depend on.
 
Predictions for treating gastric cancer - gain data to help you stay ahead
 
With our independent study you explore products, companies, progress and possibilities. Discover the best opportunities and assess commercial potentials.
 
Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort. Also discover how you could benefit your plans, decisions, presentations, proposals and influence.
 
Our new investigation shows you data, trends, opportunities and forecasts for that expanding anticancer drugs market. Avoid missing out. Instead please get our report here now.
 
visiongain is a trading partner with the US Federal Government.
 
TABLE OF CONTENTS
 
1. Report Overview
1.1. Gastric Cancer Therapeutics: Market Overview
1.2. Global Gastric Cancer Therapeutics Market Segmentation
1.3. Why You Should Read This Report
1.4. How This Report Delivers
1.5. Main Questions Answered by This Analytical Study
1.6. Who is This Report For?
1.7. Methods of Research and Analysis
1.8. Frequently Asked Questions (FAQ)
1.9. Associated Visiongain Reports
1.10. About Visiongain
 
2. Introduction to Gastric Cancer Treatment
2.1. Stomach Cancer: An Overview
2.2. Treatments for Stomach Cancer
2.3. Defining the Gastric Cancer Therapies Market
 
3. Leading Stomach Cancer Drugs
3.1. Herceptin (trastuzumab) - Roche: The First Targeted Drug Approved as a Gastric Cancer Treatment
3.1.1. Herceptin: Treatment of HER2+ Cancer
3.1.2. Herceptin: Method of Administration and Side Effects
3.1.3. ToGA: Pivotal Herceptin Study Led to Approvals
3.1.4. ToGA Trial Results
3.1.4.1. Further Possibilities from the ToGA Results
3.1.5. Herceptin Revenue Forecast 2015-2026: Losing Battle with Biosimilar Trastuzumab
3.2. Cyramza (ramucirumab) - Eli Lilly
3.2.1. REGARD and RAINBOW: Pivotal Cyramza Clinical Trials
3.2.2. Cyramza: VEGF Targeting for the Inhibition of Angiogenesis
3.2.3. Cyramza's Development: Potential as a Combination Treatment
3.2.4. Cyramza Revenue Forecast 2015-2026
3.3. Taxotere (docetaxel) - Sanofi
3.3.1. Taxotere Revenue Forecast 2015-2026
3.4. Xeloda (capecitabine) - Roche
3.4.1. Xeloda Revenue Forecast 2015-2026
3.5. Abraxane (paclitaxel protein-bound particles) - Celgene/ Taiho Pharmaceutical/Otsuka Pharmaceutical
3.5.1. Abraxane Revenue Forecast 2015-2026
3.6. TS-1 (S-1/Teysuno) - Taiho Pharmaceutical/Otsuka Pharmaceutical
3.6.1. TS-1 Revenue Forecast 2015-2026
3.7. Apatinib (YN968D1) - Jiangsu Hengrui Medicine/LSK BioPartners/Bukwang Pharmaceutical Company
3.7.1. Apatinib Revenue Forecast 2015-2026
 
4. The Gastric Cancer Treatment R&D Pipeline Analysis 2016-2026
4.1. The Importance of R&D in the Gastric Cancer Treatment Industry
4.2. Perjeta (pertuzumab) - Roche - A Novel HER2 Targeting Mechanism
4.3. Opdivo (nivolumab/ONO-4538) - Bristol-Myers Squibb
4.4. Keytruda (pembrolizumab/MK3475) - Merck/MSD
4.5. TAS-118 - Taiho Pharmaceutical/Otsuka Pharmaceuticals
4.6. TAS-102 - Taiho Pharmaceutical/Otsuka Pharmaceuticals/Servier
4.7. NeuVax (nelipepimut-S) - Galena Biopharma/Dr. Reddy's Laboratories
4.8. Ipatasertib (GDC-0068/RG7440) - Genentech/Roche/Array BioPharma
4.9. Durvalumab (MEDI4736) - AstraZeneca/MedImmune
4.10. Avelumab- (MSB0010718C) - Merck KGaA/Pfizer
4.11. Claudiximab (IMAB362) - Ganymed Pharmaceutical
4.12. Napabucasin (BBI608) - Boston Biomedical
4.13. AZD4547 - AstraZeneca
4.14. Dovitinib (TKI258) - Novartis
4.15. The Future of the Gastric Cancer Treatment Landscape: Other Compounds of Future Interest
 
5. Global Gastric Cancer World Market 2015 to 2026: Forecasts and SWOT Analysis
5.1. The Global Gastric Cancer Treatment Market Forecast 2015-2026
5.2. World Revenue Forecasts 2015-2026: Changing Market Shares for the Gastric Cancer Treatment Market
5.3. Chemotherapy Segment Forecast, 2015-2026
5.4. Monoclonal Antibodies Segment Forecast, 2015-2026
5.5. Angiogenesis Inhibitors Segment Forecast, 2015-2026
5.6. Drivers and Restraints of the Gastric Cancer Treatment Market 2015 to 2026
5.6.1. Factors Driving Growth in the Gastric Cancer Treatment Market 2015 to 2026
5.6.1.1. A Rise in the At-Risk Population Will Drive Growth
5.6.1.2. Premium-Pricing of Drugs Will Generate Revenue
5.6.1.3. There is High Unmet Need for Novel Treatments to Improve Poor Prognosis
5.6.1.4. Biomarker Development is Critical to Improving Diagnosis and Prognosis of Gastric Cancer
5.6.1.5. Combination Therapies: Lowering Associated Toxicities and Improving the Safety Profile for Treatments
5.6.2. Factors Restraining the Gastric Cancer Treatment Market 2015 to 2026
5.6.2.1. Loss of Patent Protection Will Open the Market to Generic and Biosimilar Erosion
5.6.2.2. Affordability of Treatment Will Restrain Market Growth Because of Healthcare Budgets
5.6.2.3. Patients are Developing Resistance to Treatment
5.7. SWOT Analysis of the Gastric Cancer Treatment Market 2015 to 2026
 
6. Leading National Markets for the Gastric Cancer Treatment Market 2015-2026
6.1. Regional Breakdown of the World Gastric Cancer Treatment Market
6.2. World Gastric Cancer Treatment Market: Regional Forecasts 2015-2026
6.2.1. How Will Regional Market Shares Change to 2026?
6.3. The US Gastric Cancer Treatment Market 2015 to 2026
6.4. The EU5 Gastric Cancer Treatment Market 2015 to 2026
6.4.1. The Gastric Cancer Treatment Market in Germany to 2026
6.4.2. The Gastric Cancer Treatment Market in Italy to 2026
6.4.3. The Gastric Cancer Treatment Market in Spain to 2026
6.4.4. The Gastric Cancer Treatment Market in France to 2026
6.4.5. The Gastric Cancer Treatment Market in UK to 2026
6.5. The Japanese Gastric Cancer Treatment Market 2015-2026
6.6. The Gastric Cancer Treatment Market in the Emerging Market: BRIC Market Forecast 2015-2026
6.6.1. The Gastric Cancer Treatment Market in China to 2026
6.6.2. The Gastric Cancer Treatment Market in Brazil to 2026
6.6.3. The Gastric Cancer Treatment Market in Russia to 2026
6.6.4. The Gastric Cancer Treatment Market in India to 2026
 
7. Research Interview
7.1. Interview with Dr Jun Cai, MD, PhD, Senior Research Fellow, Cardiff China Research Collaborative, Cardiff University, Cardiff, Wales, UK
7.1.1. Biomarkers: An Opportunity in Gastric Cancer Treatment
7.1.2. Challenges in Developing Gastric Cancer Treatments
7.1.3. The Benefits of Using Biomarkers
7.1.4. Targeted Treatment: VEGF Inhibitors
 
8. Conclusions
8.1. The World Gastric Cancer Treatment Market in 2015
8.2. Market Share Distribution Will Differ Over the Forecast Period
8.3. Leading Gastric Cancer Treatment Drug Companies
8.4. National Market Segments: Changes in Market Share Over the Forecast Period
8.5. Concluding Remarks: The Future of the Gastric Cancer Treatment Market
 
List of Tables
Tabel 3.1: FDA Approved Indications of Herceptin
Table 3.2: Selected Approval Dates for Herceptin for Gastric Cancer Treatment by Region
Table 3.3: Herceptin Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.4: Herceptin Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.5: FDA Approvals for Cyramza
Table 3.6: Selected Approvals for Cyramza for Gastric Cancer Treatment by Region
Table 3.7: Selected Cyramza Phase 1 and 2 Clinical Trials, 2016
Table 3.8: Cyramza Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.9: Cyramza Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.10: Taxotere Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.11: Taxotere Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.12: Xeloda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.13: Xeloda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.14: Abraxane Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.15: Abraxane Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.16: TS-1 Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.17: TS-1 Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.18: Selected Clinical Trials for Apatinib, 2016
Table 3.19: Apatinib Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.20: Apatinib Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 4.1: Selected Gastric Cancer Pipeline Developments, 2016
Table 4.2: HER2 Structure
Table 4.3: S-1 Structure, 2016
Table 4.4: Other Compounds of Interest for Gastric Cancer Treatment, 2016
Table 5.1: Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 5.2: Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 5.3: Top Three Gastric Cancer Treatment Drugs by Revenue ($bn), 2015
Table 5.4: Global Market for Gastric Cancer Drug Treatments: Revenues ($bn) and Market Shares (%) by Class, 2015
Table 5.5: Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2015-2020
Table 5.6: Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2021-2026
Table 5.7: Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Changing Market Shares (%), 2015-2026
Table 5.8: Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.9: Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.10: Monoclonal Antibodies Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.11: Monoclonal Antibodies Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.12: Angiogenesis Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.13: Angiogenesis Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.14: SWOT: Strengths, Weaknesses, Opportunities and Threats in the Gastric Cancer Treatment Market, 2016-2026
Table 6.1: Gastric Cancer Treatment Market: Revenues ($bn) and Market Shares (%) by Region, 2015
Table 6.2: Gastric Cancer Treatment Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.3: Gastric Cancer Treatment Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.4: US Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.5: US Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.6: EU5 Gastric Cancer Treatment Market: Revenue ($bn) and Market Share (%) by Leading Country, 2015
Table 6.7: EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.8: EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.9: German Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.10: German Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.11: Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.12: Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.13: Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.14: Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.15: French Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.16: French Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.17: UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.18: UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.19: Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.20: Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.21: Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Top Country, 2015
Table 6.22: Gastric Cancer Treatment Market: Leading Emerging Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.23: Gastric Cancer Treatment Market: Leading Emerging Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.24: Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.25: Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.26: Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.27: Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.28: Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.29: Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.30: Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.31: Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 8.1: Gastric Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2015, 2020, and 2026
Table 8.2: Gastric Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2015, 2020, and 2026
 
List of Figures
Figure 1.1: Global Gastric Cancer Therapeutics Market Segmentation Overview, 2016
Figure 3.1: Herceptin Forecast: Revenue ($bn), 2015-2026
Figure 3.2: Cyramza Forecast: Revenue ($bn), 2015-2026
Figure 3.3: Taxotere Forecast: Revenue ($bn), 2015-2026
Figure 3.4: Xeloda Forecast: Revenue ($bn), 2015 -2026
Figure 3.5: Abraxane Forecast: Revenue ($bn), 2015-2026
Figure 3.6: TS-1 Forecast: Revenue ($bn), 2015-2026
Figure 3.7: Apatinib Forecast: Revenue ($bn), 2015-2026
Figure 5.1: Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 5.2: Global Market for Gastric Cancer Treatments: Market Shares by Class (%), 2015
Figure 5.3: Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), 2015 to 2026
Figure 5.4: Global Market for Gastric Cancer Treatment Drugs by Class: Market Shares (%), 2020
Figure 5.5: Global Market for Gastric Cancer Treatment Drugs by Class: Market Shares (%), 2026
Figure 5.6: Chemotherapy Segment: Revenues ($bn), 2015-2026
Figure 5.7: Monoclonal Antibodies Segment: Revenues ($bn), 2015-2026
Figure 5.8: Angiogenesis Inhibitors Segment: Revenues ($bn), 2015-2026
Figure 5.9: Gastric Cancer Treatment Market: Main Drivers and Restraints, 2016-2026
Figure 6.1: Gastric Cancer Treatment Market: Share (%) by Region, 2015
Figure 6.2: Forecast of Regional and National Gastric Cancer Treatment Market, Revenue ($bn), 2015-2026
Figure 6.3: Gastric Cancer Treatment Market: Share (%) by Region, 2020
Figure 6.4: Gastric Cancer Treatment Market: Share (%) by Region, 2026
Figure 6.5: US Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.6: EU5 Gastric Cancer Treatment Market: Share (%) by Country, 2015
Figure 6.7: EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), 2015-2026
Figure 6.8: German Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.9: Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.10: Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.11: French Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.12: UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.13: Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.14: Gastric Cancer Treatment Market: Emerging Market Share (%) by Top Country, 2015
Figure 6.15: Forecast of the Emerging Gastric Cancer Treatment Market, Revenue ($bn), 2015-2026
Figure 6.16: Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.17: Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.18: Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.19: Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 8.1: The Gastric Treatment Market Forecast by Class: Market Sizes ($bn), 2015, 2020, and 2026
Figure 8.2: Gastric Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2015, 2020, and 2026
 
Companies Listed
Abraxis Bioscience
Agilent Technologies
American Association for Cancer Research
Amgen
AMNOG (Act of the Reform of the Market for Medicinal Products)
Apotex
Array BioPharma
ASCO (American Society of Clinical Oncology)
AstraZeneca
Biocad
Biocon
Boston Biomedical (subsidiary of Sumitomo Dainippon Pharma)
British Association for Cancer Research
Bukwang Pharmaceutical Company
Cancer Foundation
Cardiff China Research Collaborative
Cardiff University
Celgene
Celltrion
CFDA (China Food and Drug Administration)
CHMP (Committee for Medicinal Products for Human Use)
Chugai Pharmaceutical
Chugai Pharmaceuticals
CP Guojian Pharmaceutical
Dako (subsidiary of Agilent Technologies)
Dr. Reddy's Laboratories
EC (European Commission)
EFPIA (European Federation of Pharmaceutical Industries and Associations)
Eli Lilly
Emcure Pharmaceuticals
EU (European Union)
European Association for Cancer Research
European Organisation for Research and Treatment and Cancer (EORTC)
FDA (US Food and Drug Administration)
Galena Biopharma
Ganymed Pharmaceutical
Genentech (subsidiary of Roche)
Halozyme Therapeutics
Hospira
Japanese Society of Pathology
Jiangsu Hengrui Medicine
KFDA (Korea Food and Drug Administration)
LSK BioPartners
Medarex
MedImmune (subsidiary of AstraZeneca)
Merck & Co
Merck (MSD)
Merck KGaA
Merck Serono (subsidiary of Merck KGaA)
MFDS (Korean Ministry of Food and Drug Safety)
MHLW (Ministry of Health, Labour, and Welfare)
Ministry of Health
Mylan
NanoString Technologies
NHS (National Health Service)
NICE (the National Institute for Health and Care Excellence)
Novartis
ONO Pharmaceutical
Otsuka Pharmaceutical
Otsuka Pharmaceutical/Otsuka Group
Pfizer
PMDA (Pharmaceuticals and Medical Devices Agency)
Puma Biotechnology
Roche
Sanofi
Servier
Sumitomo Dainippon Pharma
Taiho Pharmaceutical
UCLA (University of California, Los Angeles)
Unified Health System (SUS, Sistema Único de Saúde)
United Nations
US Court of Appeals
WHO (World Health Organization)
World Cancer Research Fund International

关于我们|联系我们|常见问题|服务项目|购买流程
2005-2013 All rights reserved.京ICP备05069564号-4 京公网安备110108 02010359号
全国服务热线:400-009-0050北京:010-82863481上海:021-64871266

在线客服系统